NCCN Guidelines® Insights Melanoma, Version 3.2016 Featured Updates to the NCCN Guidelines

被引：73

作者：

Coit, Daniel G. ^{[1
]}

Thompson, John A. ^{[2
]}

Algazi, Alain ^{[3
]}

Andtbacka, Robert ^{[4
]}

Bichakjian, Christopher K. ^{[5
]}

Carson, William E., III ^{[6
,7
]}

Daniels, Gregory A. ^{[8
]}

DiMaio, Dominick ^{[9
]}

Fields, Ryan C. ^{[10
,11
]}

Fleming, Martin D. ^{[12
]}

Gastman, Brian ^{[13
,14
]}

Gonzalez, Rene ^{[15
]}

Guild, Valerie ^{[16
]}

Johnson, Douglas ^{[17
]}

Joseph, Richard W. ^{[18
]}

Lange, Julie R. ^{[19
]}

Martini, Mary C. ^{[20
]}

Materin, Miguel A. ^{[21
]}

Olszanski, Anthony J. ^{[22
]}

Ott, Patrick ^{[23
]}

Gupta, Aparna Priyanath ^{[20
]}

Ross, Merrick I. ^{[24
]}

Salama, April K. ^{[25
]}

Skitzki, Joseph ^{[26
]}

Swetter, Susan M. ^{[27
]}

Tanabe, Kenneth K. ^{[28
]}

Torres-Roca, Javier F. ^{[29
]}

Trisal, Vijay ^{[30
]}

Urist, Marshall M. ^{[31
]}

McMillian, Nicole ^{[32
]}

Engh, Anita ^{[32
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA

[2] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA USA

[3] UCSF, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[4] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

[5] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[6] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA

[7] Solove Res Inst, Columbus, OH USA

[8] UC San Diego Moores Canc Ctr, La Jolla, CA USA

[9] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA

[10] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA

[11] Washington Univ, Sch Med, St Louis, MO 63130 USA

[12] Univ Tennessee, Hlth Sci Ctr, Knoxville, TN 37996 USA

[13] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA

[14] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA

[15] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA

[16] Aim Melanoma, Plano, TX USA

[17] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[18] Mayo Clin, Ctr Canc, Rochester, MN USA

[19] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[20] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[21] Yale Canc Ctr, Smilow Canc Hosp, New Haven, CT USA

[22] Fox Chase Canc Ctr, Philadelphia, PA USA

[23] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA

[24] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[25] Duke Canc Inst, Durham, NC USA

[26] Roswell Pk Canc Inst, Buffalo, NY USA

[27] Stanford Canc Inst, Stanford, CA USA

[28] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[29] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[30] City Hope Comprehens Canc Ctr, Duarte, CA USA

[31] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA

[32] Natl Comprehens Canc Network, Ft Washington, PA USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2016年 / 14卷 / 08期

关键词：

MUTATED METASTATIC MELANOMA; BRAF-MUTANT MELANOMA; EXTENDED FOLLOW-UP; OPEN-LABEL; MEK INHIBITION; IMPROVED SURVIVAL; PHASE-II; IPILIMUMAB; VEMURAFENIB; DABRAFENIB;

D O I：

10.6004/jnccn.2016.0101

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The NCCN Guidelines for Melanoma have been significantly revised over the past few years in response to emerging data on a number of novel agents and treatment regimens. These NCCN Guidelines Insights summarize the data and rationale supporting extensive changes to the recommendations for systemic therapy in patients with metastatic or unresectable melanoma.

引用

页码：945 / 958

页数：14

共 50 条

[1]

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma [J].

Andtbacka, Robert H. I. ;

Kaufman, Howard L. ;

Collichio, Frances ;

Amatruda, Thomas ;

Senzer, Neil ;

Chesney, Jason ;

Delman, Keith A. ;

Spitler, Lynn E. ;

Puzanov, Igor ;

Agarwala, Sanjiv S. ;

Milhem, Mohammed ;

Cranmer, Lee ;

Curti, Brendan ;

Lewis, Karl ;

Ross, Merrick ;

Guthrie, Troy ;

Linette, Gerald P. ;

Daniels, Gregory A. ;

Harrington, Kevin ;

Middleton, Mark R. ;

Miller, Wilson H., Jr. ;

Zager, Jonathan S. ;

Ye, Yining ;

Yao, Bin ;

Li, Ai ;

Doleman, Susan ;

VanderWalde, Ari ;

Gansert, Jennifer ;

Coffin, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) :2780-U98

[2]

[Anonymous], MEKINIST PACK INS

[3]

[Anonymous], 2015, COTELLIC PACK INS

[4]

[Anonymous], 2016, OPDIVO PACK INS

[5]

Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma [J].

Ascierto, Paolo A. ;

Minor, David ;

Ribas, Antoni ;

Lebbe, Celeste ;

O'Hagan, Anne ;

Arya, Niki ;

Guckert, Mary ;

Schadendorf, Dirk ;

Kefford, Richard F. ;

Grob, Jean-Jacques ;

Hamid, Omid ;

Amaravadi, Ravi ;

Simeone, Ester ;

Wilhelm, Tabea ;

Kim, Kevin B. ;

Long, Georgina V. ;

Martin, Anne-Marie ;

Mazumdar, Jolly ;

Goodman, Vicki L. ;

Trefzer, Uwe .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26) :3205-+

[6]

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J].

Chapman, Paul B. ;

Hauschild, Axel ;

Robert, Caroline ;

Haanen, John B. ;

Ascierto, Paolo ;

Larkin, James ;

Dummer, Reinhard ;

Garbe, Claus ;

Testori, Alessandro ;

Maio, Michele ;

Hogg, David ;

Lorigan, Paul ;

Lebbe, Celeste ;

Jouary, Thomas ;

Schadendorf, Dirk ;

Ribas, Antoni ;

O'Day, Steven J. ;

Sosman, Jeffrey A. ;

Kirkwood, John M. ;

Eggermont, Alexander M. M. ;

Dreno, Brigitte ;

Nolop, Keith ;

Li, Jiang ;

Nelson, Betty ;

Hou, Jeannie ;

Lee, Richard J. ;

Flaherty, Keith T. ;

McArthur, Grant A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2507-2516

[7]

Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[8]

MAP kinase signalling pathways in cancer [J].

Dhillon, A. S. ;

Hagan, S. ;

Rath, O. ;

Kolch, W. .

ONCOGENE, 2007, 26 (22) :3279-3290

[9]

The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort [J].

Ekedahl, H. ;

Cirenajwis, H. ;

Harbst, K. ;

Carneiro, A. ;

Nielsen, K. ;

Olsson, H. ;

Lundgren, L. ;

Ingvar, C. ;

Jonsson, G. .

BRITISH JOURNAL OF DERMATOLOGY, 2013, 169 (05) :1049-1055

[10]

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma [J].

Flaherty, Keith T. ;

Robert, Caroline ;

Hersey, Peter ;

Nathan, Paul ;

Garbe, Claus ;

Milhem, Mohammed ;

Demidov, Lev V. ;

Hassel, Jessica C. ;

Rutkowski, Piotr ;

Mohr, Peter ;

Dummer, Reinhard ;

Trefzer, Uwe ;

Larkin, James M. G. ;

Utikal, Jochen ;

Dreno, Brigitte ;

Nyakas, Marta ;

Middleton, Mark R. ;

Becker, Juergen C. ;

Casey, Michelle ;

Sherman, Laurie J. ;

Wu, Frank S. ;

Ouellet, Daniele ;

Martin, Anne-Marie ;

Patel, Kiran ;

Schadendorf, Dirk .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (02) :107-114

← 1 2 3 4 5 →